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Conclusion: In total 60 of 94 pts (63.8%) with homogenously 
pT3a pN0/cN0 R1 resected PCA received radiotherapy 
highlighting the need of adjuvant/salvage treatment in those 
pts. The efficacy of radiotherapy is documented by the fact 
that the median PSA of all irradiated pts at 80 months of 
follow up was 0.01ng/ml (0.0 – 204.9). This may be blurred 
by the influence of ADT (15 pts). However, even our small 
retrospective cohort demonstrates a biochemical recurrence 
rate of originally postoperatively PSA negative pts of 49.2%. 
Furthermore, 65.7% of these pts could be rendered at least 
temporarily PSA-free by postoperative radiation.  
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Purpose or Objective: Aim of this study was to evaluate the 
safety, in terms of acute and late toxicity and QoL in patients 
(pts) with prostate carcinoma (PCa) treated with moderately 
hypofractionated IGRT/IMRT-SIB using fiducial markers.  
 
Material and Methods: Three-hundred consecutive PCa pts 
were treated with daily on-line IGRT based on 2D (6MV) 
orthogonal images. Low risk pts received 62.1 Gy in 23 
fractions to PTV1 (prostate). Intermediate risk pts with 
probability < 15% of lymph nodes involvement (Roach’s 
equation) received 67.5 Gy and 56.25 Gy in 25 fractions to 
PTV1 and PTV2 (seminal vesicles). In high risk patients with 
probability > 15% of lymph nodes involvement, pelvic lymph 
nodes (PTV3) received 50 Gy. Acute and late toxicities were 
prospectively recorded using RTOG-EORTC scale and AUA 
score. Survival curves were calculated using the Kaplan-Meier 
method. Androgen suppressive therapy was prescribed based 
on risk categories.  
 
Results: GI and GU G ≥ 3 acute toxicity were 0.7 % and 2.0 %, 
respectively. With a median follow-up of 30 months (range: 
12-72), late GI ad GU toxicity were recorded in 4 and 18 pts, 
respectively. Based on IPSS score, no pts reported severe 
urinary symptoms, and 7.7% of pts reported moderate 
symptoms only. In terms of QoL, 91.3% declared to be 
“pleased”, 5.7% “mostly satisfied” and 1.3% “mixed” (1.7% 
not evaluable).  
 
Conclusion: Our experience confirms the safety of moderate 
hypofractionation delivered with IGRT/IMRT-SIB and a 
moderate impact on QoL in pts with PCa. Prolonged follow-up 
is needed to evaluate the results in terms of patients 
outcome. 
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Purpose or Objective: The aims of this prospective 
observational trial was to study early PSA kinetics by weekly 
PSA measurements during salvage radiotherapy (RT) for 
patients with recurrent prostate cancer in order to develop a 
predictive model for treatment outcome. 
 
Material and Methods: This prospective study included 
patients with a biochemical recurrence after prostatectomy 
referred for curative salvage RT. No previous or present anti-
hormonal treatment was allowed. All patients were 
prescribed 70 Gy in 35 fractions to the prostate bed. PSA was 
measured at baseline and then weekly during RT. A PSA 
follow-up was scheduled at 3, 6, 12, 18 and 24 months after 
RT and yearly thereafter. Treatment response was defined as 
PSA <0.1 ng/ml at these time points 
(PSA_RESP_3/6/12/18/24). Bivariate analyses of the 
association between response and clinical factors as well as 
PSA during RT were performed. Here we report the results 
for end-point PSA_RESP_6.  
 
Results: Since Sept 2012, 151 patients have reached six 
months follow-up after RT. PSA_RESP_6 was achieved in 89 
(59%) of the cases. Significant predictive clinical factors were 
proportion of positive biopsies, Gleason score, lymph node 
extirpation and surgical borders. However PSA during therapy 
was the single strongest predictive factor for PSA_RESP_6 
with a ROC AUC up to 0.92 (95% CI 0.86 – 0.95). 
 
Conclusion: We propose that PSA monitored during salvage 
RT can be used as a predictive factor for treatment outcome 
and subsequently for personalized patient management. 
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Purpose or Objective: There are different guide lines about 
delineating the post-operative prostatic fossa before EBRT. 
They all recommend that the patients should have a half full 
or comfortably filled bladder at the planning CT and at each 
fraction in order to ensure a consistent bladder volume 
throughout the whole treatment course. The aim of this 
study was to compare bladder volume variations between 1) 
a specific bladder filling protocol and 2) a simple instruction 
to the patients to keep a comfortably filled bladder before 
each treatment fraction. 
 
Material and Methods: Twenty-nine patients (median 65 y) 
with PSA-relapse planned for salvage radiation therapy were 
randomised in two groups, with different preparation 
instructions: 
1. Drinking 300 ml and empting the bladder one hour before 
planning CT and treatment fractions. (13 patients) 
2. A comfortably filled bladder before planning CT and 
treatment fractions. A pre-treatment drinking volume 
according to patient’s preference. (16 patients) 
Treatment was prescribed to 70 Gy/35/2. As a complement 
to positioning to bony anatomy a CBCT was performed once a 
week to calculate the bladder volumes. 
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Results: 
 
 
Figure 1. An example of a patient with large variation in 
bladder filling between planning CT (thin light green) and 
CBCT before a treatment fraction (thick light green). The 
planning-CT and CBCT are matched to bony anatomy. (Red 
=CTV, blue=PTV, dark green= rectum) 
The bladder volumes varied widely both within each patient 
(see example in Fig. 1), between patients in the same group 
and between the groups. 
The individual patient mean bladder volume varied from 
79±23 to 269±90 ml in group 1 and between 64±19 to 309±110 
ml in group 2. 
Furthermore, there was no difference in the group mean 
bladder volume between the groups, 138±82 ml in group 1 
and 150±92 ml in group 2 (p-value 0,59). 
 
Conclusion: The findings indicate that the use of a strict 
bladder protocol is not superior to a comfortably filled 
bladder-regime to ensure a consistent bladder volume 
throughout the whole treatment course. The conclusion 
would be to let the patient prepare according to his own 
preference with a comfortably filled bladder. This could 
result in an easier patient setup due to a more relaxed 
patient. The impact of the wide variations in bladder volume 
on toxicity and dose distribution is further to be determined. 
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Purpose or Objective: To compare patient-reported 
outcomes (PROs) with physician-assessed outcomes (PAOs) on 
gastrointestinal (GI) dysfunction pre- and post-radiotherapy 
(RT) for locally advanced prostate cancer. 
 
Material and Methods: Adverse GI effects were assessed in 
80 subjects treated with intensity-modulated RT for locally 
advanced prostate cancer (78 Gy/56 Gy in 39 fractions to the 
prostate/pelvic lymph nodes) in 2011-2012. A study-specific 
PRO and CTCAE.v.3-based PAOs were completed pre- and 
post-RT (end, 3, 6, 12, and 24 m). This study focuses on the 
18 (PROs) and 8 (PAOs) potentially RT-induced GI symptoms. 
Symptomatic subjects were considered as having PRO>Grade 
1 and PAO>Grade 0 symptom severity. Relative risk ratios 
(RR) with related 95% confidence intervals (95%CI), and p-
values (two-sided 5% significance level) were calculated for 
each symptom and follow-up time post-RT, with pre-RT 
symptom severity as the reference. 
 
Results: Across all follow-up times, significant RRs were 
observed for in total 4/18 (RR: 2-25; p<0.001-0.02) PROs and 
1/8 (RR: 2; p=0.0001-0.02) PAO (Table). Defecation urgency 
and Obstruction yielded the tightest 95%CI among the PROs, 
and Flatulence among the PAOs. The RR indicated that the 
PROs acknowledged both acute (12 symptoms) and late (3m: 
5; 6m: 4; 12m: 7; 24m: 9 symptoms) RT-induced effects, and 
that the PAOs typically focused on acute rather than late 
effects (7 vs. 1-3 symptoms). 
 
 
 
Conclusion: This study indicates that the number of 
symptoms and temporal patterns of RT-induced GI 
dysfunction in locally advanced prostate cancer depend on 
the applied assessment method. Physician-assessed outcomes 
according to CTCAE.v.3 captured acute effects, and in 
particular flatulence, whilst patient-reported outcomes 
captured both acute and late effects mainly related to 
defecation urgency and obstruction. 
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Purpose or Objective: The aim of this paper is to analyze, in 
prostate cancer patients treated with external beam 
radiotherapy (EBRT), the prognostic factors and their impact 
on the outcome in terms of Cancer Specific Overall Survival 
(CSOS), Biochemical Disease Free Survival (BDFS) and Clinical 
Disease Free Survival (CDFS). 
 
Material and Methods: From October 1999 and March 2012 
we treated by EBRT, 1080 prostate cancer patients. The 
mean age was 69.2 years. Pretreatment staging examinations 
were: digital rectal examination (DRE), pretreatment PSA 
(iPSA), abdominal ultrasound, abdominal CT scan and bone 
scan. The 87% of patients were classified as < cT2, 87% had a 
